Rubius Therapeutics Inc (NASDAQ:RUBY) – Investment analysts at Jefferies Financial Group issued their Q1 2020 EPS estimates for shares of Rubius Therapeutics in a research report issued to clients and investors on Tuesday, August 13th. Jefferies Financial Group analyst M. Yee anticipates that the company will post earnings of ($0.51) per share for the quarter. Jefferies Financial Group also issued estimates for Rubius Therapeutics’ Q2 2020 earnings at ($0.56) EPS, Q3 2020 earnings at ($0.64) EPS, Q4 2020 earnings at ($0.61) EPS and FY2021 earnings at ($2.51) EPS.
Rubius Therapeutics (NASDAQ:RUBY) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.04). During the same quarter in the prior year, the company posted ($3.33) earnings per share.
A number of other research analysts have also recently commented on RUBY. Zacks Investment Research upgraded Rubius Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 24th. Guggenheim assumed coverage on Rubius Therapeutics in a research report on Thursday, May 30th. They set a “buy” rating and a $25.00 target price for the company. HC Wainwright assumed coverage on Rubius Therapeutics in a research report on Wednesday, June 26th. They set a “buy” rating and a $40.00 target price for the company. Finally, ValuEngine raised Rubius Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $28.75.
Shares of RUBY opened at $9.99 on Thursday. Rubius Therapeutics has a 52 week low of $9.96 and a 52 week high of $26.90. The stock has a market capitalization of $897.67 million and a price-to-earnings ratio of -4.40. The company has a debt-to-equity ratio of 0.13, a quick ratio of 18.64 and a current ratio of 18.64. The stock has a fifty day moving average of $13.91 and a 200-day moving average of $15.34.
In other Rubius Therapeutics news, insider Christopher L. Carpenter sold 47,757 shares of the stock in a transaction dated Wednesday, June 19th. The stock was sold at an average price of $14.02, for a total transaction of $669,553.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert Langer sold 7,500 shares of the stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $14.94, for a total value of $112,050.00. The disclosure for this sale can be found here. 58.40% of the stock is owned by company insiders.
A number of institutional investors have recently modified their holdings of the business. FMR LLC grew its holdings in Rubius Therapeutics by 8.9% during the 1st quarter. FMR LLC now owns 7,019,730 shares of the company’s stock worth $127,057,000 after acquiring an additional 573,662 shares during the period. Baillie Gifford & Co. grew its stake in shares of Rubius Therapeutics by 2.5% in the 2nd quarter. Baillie Gifford & Co. now owns 4,234,682 shares of the company’s stock valued at $66,612,000 after buying an additional 101,831 shares during the period. BlackRock Inc. grew its stake in shares of Rubius Therapeutics by 4.9% in the 2nd quarter. BlackRock Inc. now owns 2,794,691 shares of the company’s stock valued at $43,961,000 after buying an additional 130,641 shares during the period. Vanguard Group Inc. grew its stake in shares of Rubius Therapeutics by 29.1% in the 2nd quarter. Vanguard Group Inc. now owns 2,725,717 shares of the company’s stock valued at $42,876,000 after buying an additional 614,759 shares during the period. Finally, Nikko Asset Management Americas Inc. grew its stake in shares of Rubius Therapeutics by 142.3% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,254,158 shares of the company’s stock valued at $19,728,000 after buying an additional 736,490 shares during the period. Hedge funds and other institutional investors own 95.60% of the company’s stock.
About Rubius Therapeutics
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.
Featured Article: What is a death cross?
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.